Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

zacks.com - 2026-07-01 11:45:49

Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.

seekingalpha.com - 2026-06-30 08:30:00

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

seekingalpha.com - 2026-06-29 14:12:09

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).

benzinga.com - 2026-06-29 09:24:47

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.

businesswire.com - 2026-06-26 18:00:00

Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease player with its TED franchise. Veligrotug's pivotal Phase 3 data in active and chronic TED and an FDA PDUFA date of June 30, 2026, create a near-term commercial entry point. Elegrobart, a subcutaneous follow-on asset, targets market expansion by reducing treatment barriers and is planned for a Q1 2027 BLA submission.

seekingalpha.com - 2026-06-25 01:23:18

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 00:02:19

OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Labrador, with the first drill now turning on the initial hole of the Company's fully funded 2026 exploration program. The 2026 program is expected to consist of 50 diamond drill holes designed to systematically infill between widely spaced drill holes completed along the five-kilometre-long Main Zone conductive corridor, where mineralization has been intersected in holes spaced up to one kilometre apart.

globenewswire.com - 2026-06-09 09:00:00

OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is advancing plans to target high-grade copper-rich zones identified within the Kraken magmatic sulphide system in Labrador, where drilling in 2024 intersected copper grades up to 4.15% Cu (see news release dated November 26, 2024). The Company's recently announced 50-hole drill program will provide the scale and flexibility required to systematically follow up on multiple copper-rich zones identified within the broader Kraken system.

globenewswire.com - 2026-06-05 10:00:00

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines

gurufocus.com - 2026-05-27 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare.

businesswire.com - 2026-05-27 07:00:00

OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the scope of copper-nickel sulphide mineralization traced over approximately 5 kilometres along the Main Zone. Previous drilling intersected mineralization at roughly 1-kilometre spacing, outlining the scale of the Main Zone discovery.

globenewswire.com - 2026-05-19 13:30:00

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.

fool.com - 2026-05-17 14:32:26

OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is pleased to announce that it has entered into a binding subscription agreement with Pavilion Flow- Through L.P. (2026) 1 (the “Investor”) in respect of a non-brokered private placement (the “Private Placement”) of flow-through units of the Company (the “Units”) at a price of $0.52 per Unit for aggregate gross proceeds to the Company of $750,000.

globenewswire.com - 2026-05-14 11:43:00

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten publ.

businesswire.com - 2026-05-06 23:13:00

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

seekingalpha.com - 2026-05-05 17:31:15

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that it has commenced underwritten public offerings of $150.0 million aggregate principal amount of convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $100.0 million of shares of its common stoc.

businesswire.com - 2026-05-05 16:05:00

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares are up on Tuesday as the company announced positive topline results from its REVEAL-2 Phase 3 clinical trial for elegrobart, a treatment for chronic thyroid eye disease (TED).

benzinga.com - 2026-05-05 10:21:48

Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients.

reuters.com - 2026-05-05 07:05:13

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug's PDUFA target date. We delivered positive topline data fro.

businesswire.com - 2026-05-05 07:01:00

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease (TED). Elegrobart is a subcutaneously delivered, half‑life‑extended monoclonal antibody targeting the insulin‑like growth factor‑1 rec.

businesswire.com - 2026-05-05 07:00:00

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

fool.com - 2026-04-21 15:26:26

Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,843,213 shares, an increase of 31.7% from the March 15th total of 8,233,141 shares. Approximately 10.8% of the shares of the stock are short sold. Based

defenseworld.net - 2026-04-15 02:19:08